300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Photography
Crowdfunding
Financial Services
Construction
Mobile
Cryptocurrency
Big Data
Email
Artificial Intelligence
Clean Energy
Digital Media
Non Profit
Social Impact
Energy
Google
CleanTech
Consumer
Health Care
SaaS
Enterprise Software
Local
Travel
Platforms
Film
InsurTech
Oil and Gas
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Biotechnology
Sports
Legal
Automotive
eSports
Renewable Energy
Facebook
Software
Blockchain
Theatre
Beauty
Medical
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Web3
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Recruiting
Music
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
South Africa
Moldova
Seychelles
Botswana
Paraguay
France
Denmark
Ghana
Georgia
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Kenya
Latvia
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Qatar
Bahamas
Bolivia
Bahrain
Belize
Algeria
Jersey
Estonia
Belarus
Hungary
Finland
Italy
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

C&D Emerging Investment

VC Fund

C&D Emerging Investment is a VC fund focused on Health Care and Medical. C&D Emerging Investment specializing in minority equity investment.

Total investments:
13
Last investment:
Lead investor:
8%

Last updated:

Industries C&D Emerging Investment invests in

Health CareMedicalMedical DeviceBiotechnologyPharmaceutical

Stages C&D Emerging Investment invests in

Series BSeries CSeries DVenture - Series UnknownSeries E

Countries C&D Emerging Investment invests in

China

Investment Focus

Industry

  • Health Care 6 (46%)
  • Medical 5 (38%)
  • Medical Device 4 (31%)
  • Biotechnology 3 (23%)
  • Pharmaceutical 3 (23%)
See all 17 industries →

Stage

  • Series B 3 (23%)
  • Series C 3 (23%)
  • Series D 2 (15%)
  • Venture - Series Unknown 2 (15%)
  • Series E 1 (8%)

Investments

CompanyDescriptionRoundLinks
IMPACT Therapeutics IMPACT Therapeutics
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. $55.3M / Series D / Apr 19, 2024
Bang Er Orthopedic Bang Er Orthopedic
Zhejiang Boner Medical Investment Management Co., Ltd. is a well-known professional hospital investment operator in the Yangtze River Delta, featuring major orthopaedics and rehabilitation. $109.8M / Series E / Nov 09, 2023
AccuPath AccuPath
AccuPath is a high-tech group dedicated to enhancing human life and health via the use of modern materials & manufacturing science and technology. Venture - Series Unknown / Oct 25, 2023
Oricell Therapeutics Oricell Therapeutics
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. $45M / Series B / Feb 28, 2023
Nuclei System Technology Nuclei System Technology
A notable feature of the RISC-V architecture is its open scalability to facilitate the special needs of specialized areas. It is embodied in the instruction code space and the predefined Custom command, which is convenient for specific functions such as security or intelligent acceleration under the unified development model to make the productmore competitive. Nuclei System Technology provides customers with RISC-V related training services with the most professional technology, instruction set expansion and acceleration module design services based on core RISC-V processor IP, and dedicated high performance and low power processor design services. Venture - Series Unknown / Aug 18, 2022
OriginCell OriginCell
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments.OriginCell wasfounded in 2014 and is headquartered in Shanghai, China. $120M / Series B / Aug 01, 2022
Oricell Therapeutics Oricell Therapeutics
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. $120M / Series B / Aug 01, 2022
TBSTest Technology TBSTest Technology
Yuexin Technology is a semiconductor test equipment developer specializing in R&D, production and sales of ultra-large-scale integrated circuit test equipment (ATE). Its main product is SOC test equipment, which is mainly for enterprise users of integrated circuit design, production, packaging and testing. Integrated circuit test equipment andsolutions. $74.7M / Series C / Jun 24, 2022
IMPACT Therapeutics IMPACT Therapeutics
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. Series D / Mar 14, 2022
SiBionics SiBionics
SiBionics is a medtech specialized in R&D & commercialization of implantable medical devices and medical imaging artificial intelligence. $126M / Series C / Jan 21, 2022
See all 13 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Photography
Crowdfunding
Financial Services
Construction
Mobile
Cryptocurrency
Big Data
Email
Artificial Intelligence
Clean Energy
Digital Media
Non Profit
Social Impact
Energy
Google
CleanTech
Consumer
Health Care
SaaS
Enterprise Software
Local
Travel
Platforms
Film
InsurTech
Oil and Gas
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Biotechnology
Sports
Legal
Automotive
eSports
Renewable Energy
Facebook
Software
Blockchain
Theatre
Beauty
Medical
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Web3
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Recruiting
Music
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
South Africa
Moldova
Seychelles
Botswana
Paraguay
France
Denmark
Ghana
Georgia
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Kenya
Latvia
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Qatar
Bahamas
Bolivia
Bahrain
Belize
Algeria
Jersey
Estonia
Belarus
Hungary
Finland
Italy
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does C&D Emerging Investment invest in?

C&D Emerging Investment invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did C&D Emerging Investment last invest?

The most recent investment recorded for C&D Emerging Investment closed in Apr 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
C&D Emerging Investment Find emails